Adaptimmune Therapeutics PLC (ADAP)

0.6048 0.00 (0.00%) USD  |  NASDAQ  |  Dec 20, 16:00
0.5958 -0.01 (-1.49%) After-Hours: 20:00
More

Adaptimmune Therapeutics Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for ADAP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
Biodexa Pharmaceuticals PLC --
NuCana PLC --
TC BioPharm (Holdings) PLC --
Verona Pharma PLC --
Autolus Therapeutics PLC Upgrade